Are Peptides Legal? A State-by-State Guide for Prescribers (2026)

Whether a peptide is legal depends on which peptide, how it is made and where the patient is — not on the word "peptide." FDA-approved peptides (semaglutide, tirzepatide, tesamorelin, bremelanotide and others) can be prescribed anywhere a prescriber is licensed. Compounded peptides are lawful only when the bulk ingredient qualifies under federal Section 503A and the pharmacy and prescriber meet the rules of the patient's state. "Research use only" peptides sold for human use are unapproved drugs under federal law in every state.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

What Determines Whether a Peptide Can Be Prescribed in a Given State

Layer 1: The Federal Framework

FDA-approved peptides

Many peptides are approved drugs. A review in Nature Reviews Drug Discovery counted more than 80 peptide drugs that have reached the market worldwide since insulin [1]. In the U.S. these include GLP-1 and dual-incretin agonists, tesamorelin (Egrifta), bremelanotide (Vyleesi) and others. Approved products are legal to prescribe in every state, subject to the label, ordinary standards of care and state licensure. See FDA-approved peptides in 2026.

503A compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act lets a state-licensed pharmacy compound a drug for an individually identified patient based on a valid prescription. The bulk drug substance must meet one of three tests: it complies with a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on FDA's 503A Bulks List. Compounded products are not FDA-approved, which is why reviews of compounding emphasize quality-control differences and the need for strong state oversight [2][3][4].

For nominated substances that are not yet on the Bulks List, FDA uses an interim three-category system (FDA's 503A bulk drug substance categories, updated May 14, 2026):

• Category 1 — under evaluation; may be eligible for the Bulks List. FDA's interim policy generally does not target 503A compounding with these substances while they are evaluated.
• Category 2 — FDA has identified significant safety risks; compounding with these risks enforcement action.
• Category 3 — nominated without adequate supporting information.

The difference between 503A pharmacies and 503B outsourcing facilities is covered in 503A vs 503B compounding pharmacies.

The Pharmacy Compounding Advisory Committee

The PCAC advises FDA on which substances belong on the Bulks List. On July 23–24, 2026 it voted to recommend BPC-157, KPV and TB-500 (each 8–6, 1 abstention), MOTS-c (7–5, 2), Semax (8–5, 1) and Epitalon (7–4, 1), against FDA staff, whose briefing documents proposed listing none; it voted 6–7 (1) against emideltide (DSIP) (RAPS coverage). These votes are advisory. None of the recommended peptides is on the 503A Bulks List until FDA completes notice-and-comment rulemaking, expected to run into 2027. A second meeting before the end of February 2027 will consider GHK-Cu, LL-37, Dihexa acetate, Melanotan II and PEG-MGF. Our FDA Peptide Status Tracker records each substance's current position.

"Research use only" products

Peptides sold online as "for research use only" or "not for human consumption" are not a lawful third route to patients. FDA looks at the whole of a seller's marketing. In a March 31, 2026 warning letter to Gram Peptides, the agency said that despite research-only labeling, evidence from the firm's website established that its retatrutide and tirzepatide products were intended as drugs for human use — making them unapproved new drugs. Analytical testing of related online "research" products has repeatedly found mislabeled contents [5]. Prescribing or administering these products creates professional-liability and licensure exposure in any state.

Layer 2: How State Law Layers On

Federal law sets the floor. States then regulate the people and businesses involved.

State boards of pharmacy

Each state licenses the pharmacies that dispense to its residents and adopts its own compounding rules, often incorporating USP standards (see USP 795, 797 and 800). A state can be stricter than federal law — for example by limiting which bulk substances its licensees may use or by imposing additional sterile-compounding requirements. Federal permissibility never overrides a stricter state rule.

Non-resident pharmacy licensure

A pharmacy located in one state that ships compounded medication to a patient in another generally must hold a non-resident license (or the equivalent registration) from the patient's state. This is why a pharmacy's licensure footprint, not just its location, determines where it can serve patients. Newtropin's partner pharmacy network is licensed to cover all 50 states plus D.C.; how we vet partners is described on our compliance and quality page.

Prescriber licensure where the patient is located

Medical practice is generally regulated by the state where the patient is physically located at the time of care. A physician licensed only in Florida treating a patient sitting in Georgia is, in most analyses, practicing in Georgia [6]. The Interstate Medical Licensure Compact offers a voluntary, expedited pathway to additional state licenses for qualified physicians; as of September 30, 2026 it reports 44 member states plus two territories. It speeds licensure but does not replace a license in each state. Nurse practitioners and PAs face their own state scope-of-practice and supervision rules.

Telehealth

Telehealth does not change the licensure analysis — it multiplies it. States set their own requirements for establishing a prescriber–patient relationship, informed consent and documentation, and professional bodies continue to call for policy that balances access with quality [7]. Most peptides are not controlled substances, so federal controlled-substance telemedicine rules usually do not apply, but state telehealth standards always do. For practice-building guidance see telehealth peptide prescriptions.

Specific State Actions We Could Verify

We do not publish a 50-state table of "legal" peptides, because no reliable public source maintains one and state positions change faster than a table can be kept accurate. As of October 19, 2026, the state-level action we could verify from a primary or authoritative source is:

• California — AB 2442 (Peptides). The bill would create a California Investigational Peptide and Novel Compound Research and Therapeutic Access Program, with batch testing, chain-of-custody records and reporting to the state health department. Its latest recorded status is "Held under submission" in committee, dated May 14, 2026 (CalMatters Digital Democracy). It has not been enacted.

Commentary from law firms and vendors describes state boards disciplining licensees over grey-market or research-labeled peptides, but we could not confirm specific board actions against primary sources, so we do not list them. Before prescribing, check the patient's state board of pharmacy and your own licensing board directly.

A Practical Checklist for Prescribers

1. Identify whether an FDA-approved product exists for the substance.
2. If compounding, confirm the substance's federal position on the tracker — on the Bulks List, Category 1, or not eligible.
3. Confirm the dispensing pharmacy holds a license (resident or non-resident) in the patient's state.
4. Confirm you hold a license, and any required supervision or collaboration agreement, where the patient is located.
5. Document the evaluation and informed consent to the patient state's telehealth standards.
6. Never source "research use only" products for patient use.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A partner pharmacies that together cover all 50 states and D.C.; prescribers can start at For Providers.

Frequently Asked Questions

Are peptides legal in the United States?

Some are and some are not. FDA-approved peptides are legal to prescribe; compounded peptides are lawful only if the bulk ingredient qualifies under Section 503A and state rules are met; "research use only" peptides sold for human use are unapproved drugs. Legality is substance-by-substance.

Are peptides legal in every state?

FDA-approved peptides can be prescribed in every state by appropriately licensed prescribers. For compounded peptides, the patient's state controls pharmacy licensure and may impose stricter rules than federal law, so availability can differ by state.

Can I prescribe peptides to patients in another state?

Generally only if you are licensed in the state where the patient is located at the time of care, and the dispensing pharmacy is licensed to ship there. The Interstate Medical Licensure Compact can speed additional physician licenses but does not replace them.

Are research peptides legal to buy?

Selling peptides labeled "research use only" for human use is treated by FDA as distributing unapproved drugs; FDA issued such a warning letter to Gram Peptides in March 2026. Prescribers should not use these products for patients.

Did the July 2026 PCAC vote make BPC-157 legal?

No. The committee voted 8–6 (1 abstention) to recommend BPC-157 for the 503A Bulks List, but the vote is advisory. BPC-157 is not on the Bulks List until FDA completes rulemaking, expected to run into 2027.

What does Category 1 or Category 2 mean for peptides?

They are FDA's interim categories for substances nominated to the 503A Bulks List. Category 1 substances are under evaluation and generally not targeted for enforcement; Category 2 substances raise significant safety risks. Neither category is FDA approval.

References

1. Muttenthaler M, et al. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. PubMed
2. Gudeman J, et al. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. PubMed
3. Pinkerton JV, et al. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy. Menopause. 2016;23(2):215-23. PubMed
4. Kircik L, et al. Clinical and Legal Considerations in Pharmaceutical Compounding. J Clin Aesthet Dermatol. 2023;16(8 Suppl 1):S23-S28. PubMed
5. Van Wagoner RM, et al. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004-2010. PubMed
6. Fields BG. Regulatory, Legal, and Ethical Considerations of Telemedicine. Sleep Med Clin. 2020;15(3):409-416. PubMed
7. Johnson D, et al. Telemedicine Policy and Practice: A Position Paper From the American College of Physicians. Ann Intern Med. 2026;179(7):1030-1032. PubMed